Turning down the heat: The case for mild hyperthermia and thermosensitive liposomes

A single disappointing study does not mean an end to the future of ThermoDox (R), writes Michael Tardugno (CEO of Celsion Corporation), after announcing the termination of Celsion's second Phase III clinical trial. The OPTIMA trial, as it was known, evaluated their thermosensitive liposome (TSL) formulation of doxorubicin (ThermoDox (R)) in combination with radiofrequency ablation for the treatment of hepatocellular carcinoma (HCC). The purpose of this perspective is to review the case of ThermoDox and to address questions related to its clinical translation. Specifically, what has prevented the clinical translation of this once highly regarded breakthrough technology? Is this the end of TSLs? What can we learn from the challenges faced in the clinical development of this multi-modal therapy? As formulation scientists working in the field, we continue to believe that heat-triggered drug delivery platforms have tremendous potential as chemotherapy. Herein, we highlight potential limitations in the design of many of the Thermodox clinical trials, and we propose that despite these setbacks, TSLs have the potential to become an effective component of cancer therapy. (C) 2021 Elsevier Inc. All rights reserved.

Automated summary

A single disappointing study does not mean the end for ThermoDox, which still has potential to be an effective cancer treatment. Despite challenges faced, heat-triggered drug delivery platforms still hold tremendous potential for development.